SCHEMBL2925992

SCHEMBL2925992

CC(C)CCNC(=O)[C@@H](NC(=O)c1cc2ccccc2cn1)[C@@H](C)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC2 Q92769 1/20 0.42
LAP3 P28838 2/20 0.42
ANPEP P15144 1/20 0.42
RNPEP Q9H4A4 1/20 0.42
DNPEP Q9ULA0 1/20 0.42
EGLN1 Q9GZT9 1/20 0.42
ELANE P08246 1/20 0.41
CTSG P08311 1/20 0.41
CYP3A4 P08684 1/20 0.41
PSMB1 P20618 1/20 0.41
CMA1 P23946 1/20 0.41
PSMB8 P28062 1/20 0.41
PSMB9 P28065 1/20 0.41
PSMB5 P28074 1/20 0.41
PSMB10 P40306 1/20 0.41
PSMB2 P49721 1/20 0.41
MCHR1 Q99705 1/20 0.40
HTR1A P08908 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926222 0.82 GRN (0.56) PSMB5NPC1RAB9ASMN1; SMN2
SCHEMBL2934926 0.81 EPHX2 (0.51) LAP3ANPEPRNPEPDNPEPELANE
SCHEMBL2934901 0.81 NPC1 (0.51) LAP3ANPEPRNPEPDNPEPEGLN1
SCHEMBL2932636 0.81 EGLN1 (0.41) HDAC3HDAC1HDAC2EGLN1ELANE
SCHEMBL2931763 0.81 CTSA (0.48) LAP3ANPEPRNPEPDNPEPELANE
SCHEMBL2926119 0.81 ALDH1A1 (0.50) HDAC1ELANECTSGCYP3A4PSMB1
SCHEMBL607814 0.81 ELANE (0.47) HDAC3HDAC1HDAC2ELANENPC1
SCHEMBL2933382 0.81 CYP3A4 (0.48) LAP3ANPEPRNPEPDNPEPELANE
SCHEMBL2933648 0.81 PSMB5 (0.64) HDAC3HDAC1HDAC2ELANECTSG
SCHEMBL2930877 0.81 CCR1 (0.54) HDAC3HDAC1HDAC2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 HDAC3 809/4885HDAC1 235/4885HDAC2 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.